JEFFERSONVILLE, N.Y., May 13, 2025 (GLOBE NEWSWIRE) -- Jeffersonville Bancorp, Inc. (OTCQB - JFBC) announced today first quarter net income of $2,718,000 or $0.64 per share compared to $2,553,000 or $0.60 per share for the same quarter in 2024. The increase in quarterly net income compared to 2024 of $165,000 was primarily attributable to a decrease in interest expense of $621,000, an increase in loan interest and fees of $328,000, and an increase in non-interest income of $102,000. The increase was partial ...

Core Insights - American Public Education, Inc. (APEI) reported strong first-quarter 2025 results, with adjusted earnings and total revenues exceeding expectations and showing year-over-year growth [1][2] - The performance was primarily driven by contributions from Rasmussen University (RU), American Public University System (APUS), and Hondros College of Nursing (HCN), while the Graduate School (GSUSA) segment experienced a revenue decline [1][2] Financial Performance - APEI's adjusted earnings per share (EPS) reached 41 cents, significantly surpassing the Zacks Consensus Estimate of 15 cents by 173.3%, compared to a loss of six cents per share in the same quarter last year [3] - Total revenues amounted to $164.6 million, exceeding the consensus mark of $162 million by 1.6% and growing 6.6% year over year, supported by net course registration growth and tuition increases [4] - Total costs and expenses rose 2% year over year to $152.3 million, driven by a 3.5% increase in instructional costs and an 8.5% rise in selling and promotional expenses [4] - Adjusted EBITDA increased by 24% year over year to $21.2 million, with an adjusted EBITDA margin of 13%, expanding 200 basis points from 11% [5] Segment Performance - APUS reported revenues of $83.9 million, a 4.1% increase from $80.7 million year over year, driven by net course registrations and tuition increases [6] - RU's revenues grew 11.5% year over year to $59.3 million, attributed to enrollment growth and tuition hikes, with total student enrollment increasing 7.4% to 14,500 [7][8] - HCN's revenues rose 7.5% year over year to $17.7 million, supported by student enrollment growth, although it reported a negative EBITDA margin of 1% [8][9] - GSUSA's revenues declined 11.9% year over year to $3.7 million, with a negative EBITDA margin of 57% [10] Cash and Debt Position - As of March 31, 2025, APEI had cash, cash equivalents, and restricted cash of $187.5 million, up from $158.9 million at the end of 2024 [11] - Net long-term debt slightly increased to $93.7 million from $93.4 million at the end of 2024 [11] Guidance and Outlook - For Q2 2025, APEI expects total revenues to increase by 4-5% year over year to $160-$162 million, with a projected loss per share between 13 cents and four cents [12] - Adjusted EBITDA for Q2 is anticipated to be between $11.5 million and $14 million, reflecting year-over-year growth of 6% to 28% [12] - The company revised its 2025 guidance, expecting total revenues to grow 4-6% year over year to $650-$660 million, with adjusted EBITDA projected between $77 million and $87 million [14]

Core Viewpoint - Xenon Pharmaceuticals reported a narrower loss per share in Q1 2025 compared to estimates, while also generating modest revenue from collaborations, indicating ongoing development in its pipeline despite financial challenges [1][2]. Financial Performance - The company reported a loss of 83 cents per share for Q1 2025, which is an improvement from the loss of 94 cents estimated by Zacks and a loss of 62 cents in the same quarter last year [1]. - Revenues for the first quarter were $7.5 million, slightly below the Zacks Consensus Estimate of $8 million, with no revenues reported in the year-ago quarter [2]. - Research and development (R&D) expenses increased by 38.1% year over year to $61.2 million, primarily due to costs associated with late-stage epilepsy studies and the initiation of a phase III study for major depressive disorder (MDD) [4]. - General and administrative expenses rose to $19 million, up 28.4% year over year, attributed to increased personnel-related costs [5]. - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $691.1 million, down from $754.4 million at the end of 2024, which is expected to fund ongoing clinical developments through 2027 [6]. Pipeline Developments - Xenon's lead candidate, azetukalner, is undergoing late-stage studies for focal onset seizures (FOS), with two phase III studies (X-TOLE2 and X-TOLE3) evaluating different doses [8]. - The first top-line data readout from the X-TOLE2 study is now anticipated in early 2026, delayed from the previously expected second half of 2025 [8]. - The company is also evaluating azetukalner for primary generalized tonic-clonic seizures in a phase III study and has initiated a phase III study for MDD following a successful phase II study [9]. - Plans for a late-stage bipolar depression program are set to begin by mid-2025, addressing significant unmet medical needs [10]. - The company is advancing multiple preclinical candidates targeting various indications, with plans to file an investigational new drug application for its Nav1.7 candidate, XEN1701, in Q3 2025 [11].

Core Insights - AB InBev is focused on investments to drive growth and diversify its portfolio of global, international, and craft specialty premium brands [1] - The company plans to invest $300 million in its U.S. manufacturing operations in 2025 to enhance training, recruitment, and local production [2] - This investment follows a nearly $2 billion investment in U.S. facilities over the past five years, aimed at boosting the economy and sustaining jobs [3] Investment and Operations - The investments are intended to improve internal systems at U.S. manufacturing facilities, enhancing brewery efficiency and economic prosperity [4] - AB InBev reported mixed first-quarter 2025 results, with strong earnings performance but soft sales, driven by diversified operations and demand for megabrands [5] - Revenues from megabrands increased by 4.4%, particularly benefiting from the strong performance of the Corona brand [5] Digital Transformation - The company has been rapidly growing its digital platforms, with B2B digital platforms contributing approximately 72% to revenues in Q1 2025 [6] - The omnichannel ecosystem generated $275 million in revenues during the same period [6] Beyond Beer Portfolio - AB InBev's Beyond Beer portfolio saw a revenue increase of 16.6%, driven by double-digit growth in brands like Cutwater and Nütrl in the U.S. and Beats in Brazil [7] Stock Performance - Over the past three months, AB InBev's shares have increased by 25.5%, outperforming the industry growth of 18.9% [8]

Core Viewpoint - Intuit (INTU) is positioned well to potentially beat earnings estimates in its upcoming quarterly report, supported by a strong history of exceeding expectations [1]. Company Performance - Intuit, known for TurboTax and QuickBooks, has a solid track record of surpassing earnings estimates, with an average surprise of 17.31% over the last two quarters [2]. - In the most recent quarter, Intuit reported earnings of $3.32 per share, exceeding the expected $2.58 per share by 28.68%. In the previous quarter, it reported $2.50 per share against an estimate of $2.36 per share, resulting in a surprise of 5.93% [3]. Earnings Estimates - Recent estimates for Intuit have been revised upward, with a positive Earnings ESP (Expected Surprise Prediction) indicating a strong likelihood of another earnings beat [6]. - The Zacks Earnings ESP for Intuit is currently +0.43%, suggesting analysts are optimistic about the company's earnings prospects [9]. Predictive Metrics - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have a nearly 70% chance of producing a positive surprise, indicating a high probability of beating consensus estimates [7]. - The Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions [8].

Core Insights - Kimberly-Clark Corporation is navigating a challenging consumer backdrop while evolving its business strategy to focus on volume mix-led growth [3][5] - The company has undergone a reorganization to better position itself in the market and improve its perception beyond being a "pulp proxy" [3] Company Leadership - Mike Hsu has been with Kimberly-Clark since 2012 and has served as CEO since 2019, playing a crucial role in guiding the company through industry challenges [1] - Nelson Urdaneta, the CFO, joined the company in 2022 and brings extensive experience from the consumer packaged goods sector [1] Industry Context - The industry has faced significant volatility, prompting Kimberly-Clark to adapt its strategies to maintain growth and navigate ongoing challenges [3][5]

Group 1 - Mastercard participated in the J.P. Morgan 53rd Annual Global Technology, Media and Communications Conference on May 13, 2025, with CFO Sachin Mehra representing the company [1]. - The discussion included insights on consumer spending and macroeconomic conditions, highlighting the importance of leading indicators for investors [5]. - The company is focused on tracking macroeconomic changes and is prepared to pivot its strategies to meet financial targets as necessary [5][6].

Group 1: Investment and Sustainability Initiatives - United Airlines (UAL) announced an investment in Twelve, a low-carbon fuels company that produces sustainable aviation fuel (SAF) using a process similar to photosynthesis [1] - This investment is part of UAL's Sustainable Flight Fund, which aims to support innovations that make air travel cleaner and reduce aviation emissions by 90% by 2050 [2][3] - The Sustainable Flight Fund, launched in 2023, has grown to over $200 million and focuses on expediting the development and production of SAF [3] Group 2: Financial Performance and Market Position - UAL benefits from declining oil prices, with fuel expenses decreasing by 8.6% year over year in Q1 2025, positively impacting its bottom line [5] - The company announced a $1.5 billion share buyback plan, marking its first buyback since the COVID-19 pandemic, and has repurchased shares worth $451 million through April 10 [6] - UAL is trading at a discount compared to the Zacks Transportation-Airline industry, with a Value Score of A, indicating a favorable valuation relative to peers [7] Group 3: Stock Performance and Earnings Outlook - UAL's stock has underperformed due to tariff-induced slowdowns, with shares down 19.1% year-to-date [10] - Earnings per share estimates for 2025 have declined over the past 60 days, reflecting a negative trend in earnings revisions [13] - UAL's adjusted EPS outlook for 2025 ranges from $7 to $13.50, depending on economic conditions, with high labor costs also impacting profitability [15]

Landsea Homes Corporation (LSEA) reported lackluster first-quarter 2025 results, wherein adjusted earnings and total revenues missed the Zacks Consensus Estimate. On a year-over-year basis, the bottom line tumbled while the top line grew.During the quarter, the company witnessed growth in home closing volume, which was partially offset by lower home closing average selling price (ASP), especially across Texas, Florida and Colorado markets. Reduced cancellation rates, accompanied by order growth on lower ASP ...

NVIDIA TodayNVDANVIDIA$130.95 +7.95 (+6.46%) 52-Week Range$86.62▼$195.95Dividend Yield0.03%P/E Ratio51.53Price Target$164.84Add to WatchlistNVIDIA’s NASDAQ: NVDA stock price is melting up and can extend the move to lofty levels. While little has been confirmed, easing trade tensions with China, reduced semiconductor restrictions on Arab nations, and improving economic conditions point to an improved outlook for sales and market sentiment. Up 50% from the April low to the mid-May highs, this undervalued sto ...